 Currently, concurrent chemoradiotherapy withwithout sequential chemotherapy is the standard treatment modality for intermediate risk NPC stage II and T3N0M0 according to the National Comprehensive Cancer Network guideline. However these recommendations were based on the evidence in the two-dimensional conventional radiotherapy 2DCRT era. The introduction of intensity-modulated radiotherapy IMRT in NPC treatment has brought substantial better treatment outcomes than 2DCRT. It has been questioned whether additional concurrent chemotherapy is still necessary for intermediate risk NPC within the excellent framework of IMRT. hus, we jointly conduct the first non-inferior randomized trial to determine the value of concurrent chemotherapy with cisplatin for intermediate risk NPC patients treated with IMRT. Given the results of clinical studies mentioned above, we decide to adopt the concurrent regimen to be cisplatin 100 mgm2 on day 1, 22, 43 